



   
Solid Tumour Section 
Review 
 
Atlas Genet Cytogenet Oncol Haematol. 2013; 17(3)  209 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
Breast: Ductal carcinoma 
Cathy B Moelans, Paul J van Diest 
Department of Pathology, University Medical Center Utrecht, Utrecht, Heidelberglaan 100, PO Box 85500, 
3508 GA, Utrecht, The Netherlands (CBM, PJv) 
 
Published in Atlas Database: October 2012 
Online updated version : http://AtlasGeneticsOncology.org/Tumors/DuctCarcBreastID5593.html 
DOI: 10.4267/2042/48766 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 




Infiltrating/invasive ductal carcinoma (IDC) 




IDC represents 65 to 85 percent of all breast cancers. 
IDC originates in the transition between the breast's 
milk ducts and lobuli and invades surrounding breast 
tissue. 
Classification 
Invasive ductal carcinoma is a heterogeneous group 
with many different subtypes, some of them extremely 
rare. Each of these variants is associated with another 
pathological presentation and with a different prognosis 
compared to invasive ductal carcinoma of no special 
type (NST). As shown in Figure 1, some of the most 
important subclassifications are: 
- Medullary carcinoma: younger age, association with 
BRCA1 mutation, 1-5% of breast carcinomas, rarely 
lymph node metastases, bad prognosis 
- Metaplastic carcinoma: <1% of breast carcinomas, 
association with BRCA1 mutation, bad prognosis 
- Mucinous/colloid carcinoma: older age, 1-6% of 
breast carcinomas, better prognosis 
- Inverted papillary carcinoma: 1% of all breast 
carcinomas, better prognosis, striking lymphovascular 
invasion 
- Tubular carcinoma: younger age, about 5% of breast 
carcinomas, excellent prognosis 
- Cribriform carcinoma: younger age, good prognosis. 
Clinics and pathology 
Disease 
Carcinoma of the breast is more common in the left 
breast than in the right, in a ratio of 110/100. 
Approximately 50% arise in the upper outer quadrant, 
10% in each of the remaining quadrants, and 20% in 
the central or subareolar region. While the 
overwhelming majority of breast cancer cases in 
humans are women, men can also develop breast 
cancer. 
Progression: One of the earliest detectable changes is 
loss of normal regulation of cell growth and polarity, 
resulting in early morphological changes such as 
atypical ductal hyperplasia (ADH) and columnar cell 
lesions (CCL). Next, genomic instability results in the 
formation of ductal carcinoma in situ (DCIS) lesions.  
In the most popular model to explain the development 
of IDC, low-grade DCIS lesions tend to progress to 
low-grade IDC, and high-grade DCIS tends to progress 
to high-grade IDC by accumulation of fairly specifi 
chromosomal and gene alterations (Buerger et al., 
2000; Hwang et al., 2004).  
The majority of molecular changes that are observed in 
breast cancer seem to be already evident in the DCIS 
stage (Mommers et al., 2001).  
Also, epigenetic changes such as methylation and 
microRNAs are believed to play role in the disease 
progression and occur early as well (O'Day and Lal,
2010; Jovanovic et al., 2010). 






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(3)  210 
 
Figure 1. Main breast cancer histological types. From top left to bottom right: ductal NST, medullary, tubular, cribriform, mucinous and 
(squamous) metaplastic breast cancer. 
 
Etiology 
The etiology is multifactorial with three major 
contributors to the development of breast cancer: 1) 
genetic factors, 2) hormonal influences and 3) 
environmental factors. Less than 10% of women with 
breast cancer have a family history of the disease 
(BRCA1/BRCA2 mutations, ATM, TP53). Hormonal 
influences include early menstruation, late menopause, 
nulliparity, and late age at first childbirth. 
Environmental risk factors include alcohol 
consumption and dietary fat intake. Cigarette smoking 
and caffeine consumption have not been implicated in 
breast cancer. 
Epidemiology 
Worldwide, breast cancer is the most common invasive 
cancer in women. Incidence and mortality data on 
breast cancer can be found at the International Agency 
for Research on Cancer Globocan website and at the 
SEER database of the U.S. National Cancer Institute. 
Based on rates from 2006-2008, 12.29% (1/8) of 
women born today will be diagnosed with breast cancer 
at some time during their lifetime. Breast cancer is 
rarely found before the age of 25 years (except in 
familial cases). The incidence then increases with age, 
with most women being 60 years old when diagnosed. 
The main risk factors are genetic predisposition, 
increasing age, proliferative breast disease, carcinoma 
of the contralateral breast or endometrium, radiation 
exposure (Hodgkin lymphoma), geographic influences, 
race, length of reproductive life, parity, age of first 
child (older than 30 years), obesity, and exogeneous 
estrogens (hormonal replacement therapy, oral 
contraceptives). 
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Figure 2: Breast cancer biomarkers. Top left: ERα expression. Top right: HER2 receptor overexpression (3+). Bottom left: Ki67/MIB1 
nuclear expression. Bottom right: lymph node metastasis. 
 
Clinics 
Cancers of the breast are usually first discovered by 
women or their physician as a solitary painless mass. 
The use of mammography, sonography and MRI has 
increased the detection of ductal carcinoma in situ
(DCIS) and small invasive tumors before they reach 
palpable size. These non-palpable lesions can then be 
sampled by image-guided core needle biopsies. These 
lesions are usually <1 cm in size and less than 1/5th 
will have axillary metastases. Palpable lesions, in 
contrast, are usually 2-3 cm in size when first found, 
and approximately 1/3 has already spread to axillary or 
other lymph nodes. Lymph node status is generally 
assessed through the sentinel node procedure. 
Clinical staging: 
The American Joint Committee on Cancer (AJCC) 
staging system provides a strategy for grouping patients 
with respect to prognosis. Therapeutic decisions are 
formulated in part according to staging categories but 
primarily according to tumor size, lymph node status, 
estrogen-receptor and progesterone-receptor levels in 
the tumor tissue, human epidermal growth factor 
receptor 2 (HER-2/neu) status, menopausal status, and 
the general health of the patient (Edge et al., 2010). 
Stages are subdivided as follows: 
- Stage 0: Ductal carcinoma in situ (DCIS) or lobular 
carcinoma in situ (LCIS); 5-year survival rate 93% 
- Stage 1: Invasive carcinoma 2 cm or less without 
nodal involvement and no distant metastases; 5-year 
survival rate 88% 
- Stage 2: Invasive carcinoma 5 cm or less with 
involved but movable axillary lymph nodes and no 
distant metastases, or a tumor > 5 cm without nodal 
involvement or distant metastases (5-year survival rate
74-81%) 
- Stage 3 (locally advanced): Breast cancer > 5 cm with 
nodal involvement; or any breast cancer with fixed 
axillary nodes; or any breast cancer with involvement 
of the ipsilateral internal mammary lymph nodes; or 
any breast cancer with skin involvement, pectoral and
chest wall fixation, edema, or clinical inflammatory 
carcinoma, if distant metastases are absent (5-year 
survival rate 41-67%) 
- Stage 4: any form of breast cancer with distant 
metastases (including ipsilateral supraclavicular lymph 
nodes); 5-year survival rate 15%. 
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Figure 3. Left: invasive breast carcinoma with HER2 amplification by CISH; Right: FISH showing invasive breast carcinoma with HER2 
amplification (red) and CEP17 gain (green). 
 
Pathology 
The pathologist assesses resection margins, lymph node
status, tumor size, tumor grade, mitotic activity, 
histological subtype, lymphovascular invasion, 
hormonal receptor status (by immunohistochemistry) 
and HER2 status. 
Treatment 
Surgery (mastectomy or lumpectomy, axillary node 
dissection), radiation, hormonal therapy, chemotherapy 
or combinations. A very important therapeutic strategy 
since 1998 is targeted therapy with trastuzumab, a 
humanized monoclonal antibody directed against the 
human epidermal growth factor receptor 2 (HER2, 
amplified and overexpressed in 10-15% of breast 
cancers) (Romond et al., 2005). 
Prognosis 
Prognosis and survival rates vary greatly depending on 
cancer type, grade, proliferation rate (van Diest et al., 
2004), staging and treatment. Prognosis of breast 
tumors without distant metastases depends on a number 
of histopathological factors (upon distant metastases, 
cure is unlikely): 
- Locally advanced disease (skin or skeletal muscle 
invasion) 
- Presence and number of lymph node metastases, 
including the size of metastatic deposit and invasion 
through the capsule 
- Tumor size 
- Histological subtype (NST/medullary/metaplastic vs.
tubular, cribriform, mucinous) 
- Tumor grade (Bloom and Richardson grading system 
combines tubule formation, mitotic rate and nuclear 
atypia) 
- Hormonal receptor status (estrogen and progesterone 
receptor positivity confers better prognosis; 70-80% of 
breast cancers are positive for ER/PR) 
- Proliferative rate (mitotic index, Ki-67 staining) 
- Expression of certain oncogenes (HER2, MYC) or 
loss of tumor suppressor genes (TP53, CDH1). 
Genetics 
Note 
Most breast cancer cases are sporadic, with many 
different oncogenes and tumor suppressor genes 
involved, while 5-10% are estimated to be due to an 
inherited predisposition.  
Autosomal dominant alterations in two genes, BRCA1 
and BRCA2, are likely to account for most familial 
cases of early-onset breast cancer, and for 3-4% of all 
breast cancers.  
Mutations in several other genes, including TP53, 
PTEN, STK11/LKB1, CDH1, CHEK2, ATM, MLH1, 
and MSH2, have also been associated with hereditary 




Although traditionally classical karyotyping and 
chromosome based comparative genomic hybridization 
(CGH) have yielded information on chromosomal loci 
and genes involved in breast carcinogenesis, nowadays 
molecular and cytogenetic techniques such as 
fluorescence in situ hybridization (FISH, see Figure 3 
right), (q)PCR, multiplex ligation-dependent probe 
amplification (MLPA, see Figure 4), next generation 
sequencing, and array techniques for CGH, gene 
expression, methylation and microRNAs are frequently 
used in breast cancer diagnostics and research. 
FISH, as well as its chromogenic counterparts 
C(hromogenic)ISH and S(ilver)ISH, but also MLPA 
are currently used to analyze HER2 gene amplification 
status, an important prognostic factor and predictor of 
trastuzumab, chemotherapy and hormonal therapy 
response in breast cancer.  
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Figure 4. Top: HER2 non-amplified case by multiplex ligation-dependent probe amplification (MLPA). Bottom: HER2-amplified case by 
MLPA; notice the increased peak height for 5 probes (* = HER2 probes). 
 
ISH and MLPA are generally performed as a second-
line gene amplification test in tumors for which the 
immunohistochemistry (protein expression) status for 
HER2 is equivocal (so-called 2+). Amplification of 
HER2 is usually determined as ratio of HER2 on 
CEP17, the centromere of chromosome 17 (where 
HER2 resides), to correct for a phenomenon called 
polysomy 17. However, several groups have questioned 
the value of CEP17 correction since it does not seem to 
be correlated to chromosome 17 polysomy, which in 
fact is very rare (Moelans et al., 2011). 
CGH has mainly been used in the research setting 
because of its high costs and difficulty of interprtation. 
Results of CGH have extensively been described here, 
with most frequent alterations (mainly gains and 
amplifications) on chromosomes 8, 11 and 17. A 
graphical representation of the chromosomal 
aberrations found in breast tumors can be found here. A 
possible application for CGH in diagnostics in the 
future could be the differential diagnosis 
metastasis/new primary tumor. Genetic alterations in 
the primary tumor are believed to be fairly conserved 
throughout the metastatic process and as such, 
comparison of the chromosomal profiles of primary 
tumors and metastases should show high similarity. 
Sequencing projects provide us with more insight in 
breast cancer genomic rearrangements (copy number 
alterations, breakpoints, intra- and inter-chromosomal 
rearrangements (Edgren et al., 2011). A graphical 
(Circos plot) representation of chromosomal 
rearrangements in the MCF7 breast cancer cell line can 
be found here, and illustrates the complexity of the
breast cancer genome. A series of recent next-
generation sequencing manuscripts have further 
underlined the genetic diversity of breast cancer. 
Beyond confirming recurrent somatic mutations in 
PIK3CA, TP53, AKT1, GATA3 and MAP3K1, 
potential driver mutations were identified in several 
new cancer genes including AKT2, ARID1B, CASP8, 
CDKN1B, MAP3K1, MAP3K13, NCOR1, 
SMARCD1, TBX3, MTAP, PPP2R2A, CBFB and 
MAP2K3 (Stephens et al., 2012; Banerji et al., 2012; 
Curtis et al., 2012). Next to recurrent mutations and 
deletions, recurrent fusion products have also been 
shown (Banerji et al., 2012) to be more or less present 
in certain subtypes of breast cancer. Analysis of paired 
DNA-RNA profiles revealed novel subgroups with 
distinct clinical outcomes (Curtis et al., 2012). 
Additional anomalies 
As for most human cancers, aneuploidy is frequently 
present in breast tumors. The predictive value of 
nuclear DNA content in mammary carcinoma is still 
under debate in spite of several reports indicating a 
relationship between DNA ploidy and prognosis. 
Chromosomal translocations that form fusion products 
and/or activate gene expression by promoter insertion 
are key events in hematological malignancies, but have 
been reported to be less common in epithelial cancers 
such as breast cancer. However, that view is currently 
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being challenged by array painting and next generation 
sequencing studies.  
Reciprocal and more complex balanced translocations 
seem to be far more frequent than expected. The NRG1 
gene on 8p12 seems to be translocated in 6% of breast 
cancers (Huang et al., 2004; Chua et al., 2009) and 
furthermore, several translocation break points are
located within genes, including known cancer-critical 
genes such as EP300/p300 and CTCF (Howarth et al., 
2008; Edwards, 2010).  
One of the best known translocations in a specific 
subtype of breast cancer (secretory type) is a recurr nt 
chromosomal translocation t(12;15)(p13;q25), leading 
to the formation of the ETV6-NTRK3 fusion gene 
(Vasudev and Onuma, 2011). Another well-known 
recurrent translocation in adenoid cystic carcinoma 
(ACC) of the breast, t(6;9)(q22-23;p23-24), resulting n 
a fusion of the two transcription factor genes MYB and 
NFIB (Persson et al., 2009). The fusion results in loss 
of the 3'-end of MYB, including several conserved 
binding sites for microRNAs that regulate MYB 
expression negatively. 
Genes involved and proteins 
Note 
The number of genetic alterations in breast cancer is 
immense and it is therefore not possible to elaborate on 
all of them.  
A selection was made based on the amount of 
evidence/literature present. Several of the 
genes/proteins involved in invasive ductal carcinoma 
have already been described in "Breast tumors: an 
overview". These will not be repeated here (TP53, 
HER2/ERBB2, CCND1, FGFR1, BRCA1, BRCA2, 
BRCA3, PTEN, ATM, MSH2, MLH1, PMS1, MSH3, 





The encoded protein (baculoviral IAP repeat containing 
5), also called survivin, is an adapter molecule involved 
in signal transduction, cell communication and cell 
survival. It is a component of the chromosomal 
passenger complex (CPC), a complex that acts as a key
regulator of mitosis. The BIRC5 gene is a member of 
the inhibitor of apoptosis (IAP) gene family, which 
encodes negative regulatory proteins that prevent 
apoptotic cell death. Amplification of the BIRC5 region 
(in 15-30% of breast cancers) has been shown to 
predict distant recurrence (Davis et al., 2007) and 
altered cytoplasmic to nuclear ratio of BIRC5 was 
shown to be an independent prognostic factor in breast 






The epidermal growth factor receptor 1 (EGFR, 
ERBB1) is one of the four members of the ErbB 
family. EGFR is a receptor tyrosine kinase protein hat 
binds to EGF. Binding to its ligand induces receptor 
dimerization, tyrosine autophosphorylation and leads to 
cell proliferation. EGFR is amplified in a small 
percentage (5-10%) of sporadic breast tumors but a 
broad range of amplification frequencies has been 
reported in literature (7-65%) (Lambros et al., 2007). 
EGFR amplification/overexpression is however more 
frequent in hereditary, triple negative (ER, PR and 
HER2 negative) and basal-like breast tumors (Livasy et 
al., 2006; van der Groep et al., 2004). As for IGFR1 
(see below), one of the mechanisms of resistance to the 
HER2-targeted antibody trastuzumab is cross-talk 
between EGFR and HER2, which has lead to the 
development of a dual (oral) tyrosine kinase inhibitor 






Its protein can repress transcription, possibly via its 
interaction with a multiprotein chromatin remodeling 
complex that modifies the chromatin. Its interaction 
with BRCA2 suggests that it may play a central role in 
the DNA repair function of BRCA2. It is amplified in 
7-13% of breast tumors (Hughes-Davies et al., 2003; 
Kirkegaard et al., 2008; Moelans et al., 2010). Co-
amplification of CCND1 and EMSY was shown to be 
associated with an adverse outcome in ER-positive 
tamoxifen-treated breast cancers (Brown et al., 2010). 
On the other hand, a recent study suggested that EMSY 
is unlikely to be a driver of the 11q13-q14 amplicon 
and does not have a dominant role in modulating the 
response to agents targeting cells with defective 





This gene encodes an estrogen receptor (ER alpha), a 
ligand-activated transcription factor. Upon ligand 
binding the estrogen receptor undergoes a 
conformational change allowing dimerization to form 
either homo- or heterodimers. As a dimer, the estrogen 
receptor binds to the estrogen response element (ERE) 
in the promoter region of target genes.  
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Initial reports showed an ESR1 amplification frequency 
of 20.6% in breast cancer (Holst et al., 2007) but 
subsequent studies reported considerably lower 
amplification frequencies, ranging between 5 and 10% 
(Albertson, 2008; Moelans et al., 2012). Studies have 
been contradictory with respect to its correlation with 
ER alpha protein overexpression, prognostic value as 
well as predictive value (tamoxifen response or 
resistance). ER alpha protein overexpression is preent 
in 70-80% of breast cancers and is predictive of 






This gene encodes the alpha subunit of transcription 
factor hypoxia-inducible factor-1 (HIF-1), which isa 
heterodimer composed of an alpha and a beta subunit. 
HIF-1 functions as a regulator of cellular response to 
hypoxia by activating transcription of many genes, 
including those involved in energy metabolism, 
angiogenesis and apoptosis. HIF-1 thus plays an 
essential role in tumor angiogenesis and survival 
(Semenza, 2000). Although no amplifications are 
involved (Vleugel et al., 2004), HIF1 alpha has been 
shown to be overexpressed in sporadic breast cancer, 
and even more in BRCA1-related hereditary breast 
cancer (van der Groep et al., 2008). Increased levels of 
HIF1 alpha have been associated independently with 
poor prognosis in lymph node negative breast 





Its protein is a receptor with tyrosine kinase activity. 
IGFRs mediate their intracellular actions through the 
PI3-K and RAS/RAF/MAPK signaling pathways. 
Many tumors have altered expression of IGF1R and its 
ligands and this constitutes an early event in 
tumorigenesis. IGF1R overexpression is predominantly 
seen in ER-positive breast tumors. The HER2 group 
(ER/PR negative, HER2 positive) generally shows 
reduced expression and the expression is somewhat 
heterogeneous in the triple-negative group (ER, PR and 
HER2 negative) (Bhargava et al., 2011). 
One of the mechanisms of resistance to the HER2-
targeted antibody trastuzumab is cross-talk between th  
insulin-like growth factor-I receptor and HER2 (Jin a d 
Esteva, 2008). In addition to its therapeutic potential in 
HER2-positive trastuzumab-resistant tumors, targetin  
the IGF1R also shows therapeutic potential in basal-
like breast cancers, a group of aggressive tumors of 
poor prognosis for which there is no effective targeted 





c-myc is a nuclear protein that plays a role in cell ycle 
progression, apoptosis and cellular transformation. It 
functions as a transcription factor that regulates 
transcription of specific target genes. It is amplified in 
9-15% of breast cancers but a broad range of 
amplification frequencies has been reported (between 1 
and 94%) (Lambros et al., 2007; Jensen et al., 2009). 
MYC amplification has generally been associated with 
a worse prognosis, with higher mitotic activity and 
larger tumor size (Moelans et al., 2010). In human 
breast tumors, MYC amplification has been associated 
with HER2 amplification and HER2-amplified breast 
tumors were shown to have a 2.5-fold or greater 
increased likelihood of having MYC amplification (Al-
Kuraya et al., 2004). Patients with MYC/HER2 co-
amplification were observed to have substantially 
worse outcomes than patients who had single-gene 
amplification, even after standard chemotherapy. 
However, it was subsequently shown that patients wih
MYC/HER2 co-amplification in their primary breast 
tumors benefited significantly more from trastuzumab 
than did patients with only HER2 amplification. This 
could, however, not be confirmed in a later study 





Functions as a receptor for membrane-bound ligands 
Jagged1, Jagged2 and Delta1. Upon ligand activation 
through the released NOTCH1 intracellular domain 
(NICD) it forms a transcriptional activator complex. 
NOTCH1 affects multiple cellular processes including 
stem cell maintenance, cell fate, differentiation, 
proliferation, motility and survival (Reedijk, 2012). 
Aberrant NOTCH1 activity influences breast cancer 
progression through these processes and NOTCH1 
activity seems to participate in cancer metastasis by 
modulating the EMT, angiogenesis, and anoikis-
resistance of tumor cells (Hu et al., 2012). Aberrant 
NOTCH signaling can induce breast carcinoma in 
transgenic mice, and high expression of NOTCH 
receptors and ligands has been linked to poor clinical 






PI 3-Kinases (phosphoinositide 3-kinases, PI3Ks) 
coordinate a diverse range of cell functions including 
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proliferation, cell survival, degranulation, vesicular 
trafficking and cell migration. PIK3CA activating 
mutations show a high prevalence in breast cancer 
(34%) (Cizkova et al., 2012) and are associated with 
higher age at diagnosis, hormone receptor positivity, 
HER2 negativity, lower tumor grade and stage, and 
lymph node negativity. PIK3CA mutations have been 
associated with significantly longer metastasis-free 
survival, especially in the PR-positive and HER2-
positive subgroups (Cizkova et al., 2012). The majority 
of mutations occur at three hotspots, making these ideal 





This gene was identified as a tumor suppressor that is 
mutated in a large number of cancers at high frequency. 
The protein encoded this gene is a 
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase 
that antagonizes the PI3K-AKT/PKB signaling 
pathway and thereby modulates cell cycle progression 
and cell survival. About 25-50% of women with 
Cowden disease, a syndrome associated with germ-line 
mutations of the PTEN gene (at 10q23), develop breast 
cancer, but PTEN mutations have been found in only 
5% of sporadic breast cancers. However, 29-48% of 
breast cancers display loss of heterozygosity in 10q23, 
about 40% of breast cancers show a decrease or 
absence of PTEN protein levels at the time of diagnosis 
(Garcia et al., 2004) and PTEN promoter 
hypermethylation was reported to be a common event 
in sporadic breast cancer, occurring in 20-50% of 
breast cancers (Khan et al., 2004). 
PTEN not only antagonizes tumorigenesis but also 
sensitizes breast cancers to targeted therapy with 
trastuzumab (Pandolfi, 2004). Its loss has therefore 






This receptor binds retinoic acid, the biologically active 
form of vitamin A which mediates cellular signalling in 
embryonic morphogenesis, cell growth and 
differentiation. RXR-RAR heterodimers act as ligand-
dependent transcriptional regulators by binding to the 
specific retinoic acid response element (RARE) found 
in the promoter regions of target genes. In the absence 
of a RAR agonist, RXR-RAR recruits co-repressor 
proteins and associated factors such as histone 
deacetylases to maintain a condensed chromatin 
structure. RAR agonist binding stimulates co-repressor 
release and co-activator complexes, such as histone 
acetyltransferase, are recruited to activate transciption. 
The RARB2 promotor region was shown to be 
methylated in 20-25% of breast cancers and 
methylation was shown to be an independent important 
determinant of breast cancer prognosis (Sharma et al., 





This gene encodes a protein similar to the RAS effector 
proteins. Loss or altered expression of this gene has 
been associated with a variety of cancers, which 
suggests a tumor suppressor function. The inactivation 
of this gene was found to be correlated with the 
hypermethylation of its CpG-island promoter region. 
The encoded protein was found to interact with DNA 
repair proteins and was also shown to inhibit the 
accumulation of cyclin D1, and thus induce cell cycle 
arrest. The most important isoform for breast cancer 
seems to be isoform A. The frequency of RASSF1A 
methylation in breast tumors is high (65%) and 
methylation in tumor samples and fine-needle aspirate 
washings was shown to be an independent predictor of 
poor prognosis (Sharma et al., 2009; Buhmeida et al., 
2011; Martins et al., 2011). RASSF1A methylation is 
an attractive biomarker for early cancer detection and 
its methylation analysis is applicable to a range of body 






The protein encoded by this gene is a non-receptor 
protein tyrosine kinase that plays pivotal roles in 
numerous cellular processes such as proliferation, 
migration, and transformation. Src kinases are key 
upstream mediators of both the PI3-K and MAPK 
signaling pathways, and have been shown to have 
important roles in cell proliferation, migration and 
survival. c-SRC (SRC) is a key modulator of 
trastuzumab response and a common node downstream 
of multiple trastuzumab resistance pathways (Zhang et 
al., 2011). SRC is activated in both acquired and de 
novo trastuzumab-resistant cells and regulation 
involves dephosphorylation by PTEN. Increased SRC 
activation conferred considerable trastuzumab 
resistance in breast cancer cells and correlated with
trastuzumab resistance in patients. Targeting SRC in 
combination with trastuzumab sensitized multiple lines 
of trastuzumab-resistant cells to trastuzumab and 
eliminated trastuzumab-resistant tumors in vivo, 
suggesting the potential clinical application of this 
strategy to overcome trastuzumab resistance (Zhang et 
al., 2011). Furthermore, early-phase clinical trials using 
the src-inhibitors dasatinib and bosutinib have 
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suggested modest activity as monotherapy in breast 
cancer, with potentially greater activity in combination 
regimens. Given the interaction between SRC and the 
estrogen receptor, ongoing trials are exploring 
combinations with endocrine therapy. The relationship 
between SRC and the vascular endothelial growth 
factor receptor also justifies investigation of 






This gene encodes a DNA topoisomerase, an enzyme 
that controls and alters the topologic states of DNA 
during transcription. This nuclear enzyme is involved 
in processes such as chromosome condensation, 
chromatid separation, and the relief of torsional stress 
that occurs during DNA transcription and replication. It 
catalyzes the transient breaking and rejoining of two
strands of duplex DNA which allows the strands to 
pass through one another, thus altering the topology of 
DNA. It is amplified in 5-10 % of breast tumors but 
amplification is not correlated with overexpression (Di 
Leo et al., 2002; Knoop et al., 2005; Moelans et al., 
2010). TOP2A has been suggested to be a predictive 
marker of anthracyclin benefit (Nielsen et al., 2008) but 






TWIST1 is a basic helix loop helix protein that plays a 
role both in human development and in cancer 
biogenesis. It is an anti-apoptotic and pro-metastaic 
transcription factor that is known to repress E-cadherin 
expression in breast cancer (Vesuna et al., 2008) as 
well as ERα expression thereby contributing to the 
development of hormone resistance (Vesuna et al., 
2012). It is overexpressed in many epithelial cancers 
including breast cancer. Twist overexpression in breast 
cancer cells can induce angiogenesis, correlates with 
chromosomal instability, and promotes an epithelial-
mesenchymal-like transition (EMT) that is pivotal for 
the transformation into an aggressive breast cancer 
phenotype (Mironchik et al., 2005). TWIST1 promoter 
methylation is significantly more prevalent in 
malignant compared with healthy breast tissue and is 
therefore useful as a biomarker in breast cancer 
diagnosis, although there is no direct correlation with 
TWIST1 expression (Gort et al., 2008). 
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